DrugPatentWatch Database Preview
Patents Expiring in August 2027
» See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | PRADAXA | dabigatran etexilate mesylate | CAPSULE;ORAL | 022512-002 | Oct 19, 2010 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | ||
| Boehringer Ingelheim | PRADAXA | dabigatran etexilate mesylate | CAPSULE;ORAL | 022512-003 | Nov 20, 2015 | RX | Yes | No | Start Trial | Start Trial | Y | Y | |||
| Boehringer Ingelheim | PRADAXA | dabigatran etexilate mesylate | CAPSULE;ORAL | 022512-001 | Oct 19, 2010 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Y | ||
| Teva | AZILECT | rasagiline mesylate | TABLET;ORAL | 021641-001 | May 16, 2006 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Y | TREATMENT OF PARKINSON'S DISEASE | |
| Teva | AZILECT | rasagiline mesylate | TABLET;ORAL | 021641-002 | May 16, 2006 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | TREATMENT OF PARKINSON'S DISEASE | |
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | ||||
| Meridian Medcl | ALSUMA | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022377-001 | Jun 29, 2010 | DISCN | No | No | Start Trial | Start Trial | Y | ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
